Gallstone Pancreatitis (Acute Biliary Pancreatitis)

Gallstone pancreatitis is an acute inflammatory condition of the pancreas caused by obstruction of the biliary and pancreatic outflow by a gallstone, leading to activation of pancreatic enzymes within the pancreas, autodigestion, inflammation, and tissue damage (Fugazzola et al., EClinicalMedicine, 2024). It is the most common cause of acute pancreatitis, accounting for roughly 35–50% of all cases in Western countries, with an overall incidence of acute pancreatitis of about 40 per 100,000 people per year (McDermott et al., JAMA Surgery, 2024; Gardner, Yamada's Textbook of Gastroenterology, 2022).

The disease spans a wide severity spectrum. About 80% of cases are mild and self-limited, resolving with supportive care, while a minority progress to moderately severe or severe disease with complications such as pancreatic necrosis, organ failure, and pseudocysts, carrying a mortality as high as 30% (McDermott et al., JAMA Surgery, 2024). A defining feature of gallstone pancreatitis is its tendency to recur: without definitive treatment, roughly 8% of patients have a recurrent attack within weeks, rising to about 22% within five years — which is why gallbladder removal is central to management (Mederos et al., JAMA, 2021).

Characteristically, the stones responsible are small and numerous, which allows them to slip through the cystic duct and transiently impact at the ampulla before most pass into the intestine (McDermott et al., JAMA Surgery, 2024). Because the obstruction is usually transient and the stones are small, associated bile duct infection (cholangitis) is relatively uncommon, and routine ERCP is not needed in most patients (McDermott et al., JAMA Surgery, 2024).

‍

Gallstone pancreatitis develops when a gallstone migrates from the gallbladder and obstructs the common channel at the ampulla of Vater, where the bile duct and pancreatic duct join before emptying into the duodenum (van Laarhoven et al., Cochrane Database, 2018):

• Migrating gallstones (the direct cause) — small stones pass from the gallbladder into the common bile duct and transiently impact at the ampulla, obstructing pancreatic outflow (Gardner, Yamada's Textbook of Gastroenterology, 2022).

• Ductal obstruction and enzyme activation — the blockage raises pressure in the pancreatic duct and/or allows reflux of bile into the pancreatic duct, triggering premature activation of trypsinogen to trypsin, which sets off autodigestion of the pancreas (Mederos et al., JAMA, 2021).

• Microlithiasis and biliary sludge — tiny stones and sludge, often invisible on routine imaging, account for a meaningful share of otherwise "idiopathic" acute pancreatitis (Şurlin et al., World Journal of Gastroenterology, 2014).

The stones that cause pancreatitis tend to be less than 5 mm in diameter, whereas larger stones (>8 mm) more often stay in the gallbladder (Gardner, Yamada's Textbook of Gastroenterology, 2022).

‍

Because the underlying problem is gallstone disease, the risk factors mirror those for gallstones, with some features specific to who develops pancreatitis (Gardner, Yamada's Textbook of Gastroenterology, 2022):

• Pre-existing gallstones, especially small stones and microlithiasis

• Prior biliary symptoms — a history of biliary colic raises suspicion

• Age 50–60 and older

• Female sex — gallstones are far more common in women, though among people with gallstones, men develop pancreatitis more often (Gardner, Yamada's Textbook of Gastroenterology, 2022)

• Obesity and the metabolic syndrome

• Rapid weight loss or crash dieting

• Pregnancy, oral contraceptive, or estrogen use

• Family history and genetic predisposition to gallstones

‍

The pancreas secretes powerful digestive enzymes that normally remain inactive until they reach the intestine (Mederos et al., JAMA, 2021). In gallstone pancreatitis, a stone obstructs the ampulla, raising pressure within the pancreatic duct and causing enzyme-rich fluid to accumulate in the pancreatic tissue (Mederos et al., JAMA, 2021).

This precipitates inappropriate activation of trypsinogen to trypsin within the acinar cells — the functional units of the pancreas — which then activates a cascade of other digestive enzymes, the kinin system, and the complement cascade, resulting in autodigestion of the pancreatic parenchyma (Mederos et al., JAMA, 2021). The ensuing inflammation can remain confined to the pancreas (mild disease) or spill over into a systemic inflammatory response, producing the organ dysfunction, fluid collections, and necrosis that characterize severe disease (van Laarhoven et al., Cochrane Database, 2018). Severity typically declares itself within the first 24–48 hours, which is why early assessment guides management and the timing of surgery (McDermott et al., JAMA Surgery, 2024).

‍

Gallstone pancreatitis can lead to both pancreatic and biliary complications (McDermott et al., JAMA Surgery, 2024; Fogel & Sherman, NEJM, 2014):

• Pancreatic necrosis — death of pancreatic tissue, which may become infected (infected necrotizing pancreatitis)

• Pseudocysts and peripancreatic fluid collections

• Systemic inflammatory response syndrome (SIRS) and multiorgan failure — the main drivers of early death

• Pancreatic insufficiency — impaired digestion or diabetes after severe disease

• Recurrent acute pancreatitis — about 8% within weeks and up to 22% within 5 years without cholecystectomy (Mederos et al., JAMA, 2021)

• Associated biliary complications — concurrent choledocholithiasis, cholangitis, or cholecystitis, which may occur in up to 30% of patients if the gallbladder is not removed (Portincasa & Wang, Yamada's Textbook of Gastroenterology, 2022)

Overall mortality is approximately 5% across all patients with acute pancreatitis but rises to 20–30% in severe cases, and higher still with progressive multisystem organ failure (Fogel & Sherman, NEJM, 2014; Fugazzola et al., EClinicalMedicine, 2024).

‍

The hallmark is sudden, severe upper-abdominal pain with nausea and vomiting (Fugazzola et al., EClinicalMedicine, 2024):

• Pain — acute onset of persistent, severe epigastric (upper-middle) abdominal pain that often radiates to the back, a defining feature of acute pancreatitis (Fugazzola et al., EClinicalMedicine, 2024).

• Nausea and vomiting (Mederos et al., JAMA, 2021).

• Fever and rapid heart rate — reflecting inflammation and the systemic response (van Laarhoven et al., Cochrane Database, 2018).

• Jaundice — yellowing of the skin and eyes when a stone persistently obstructs the bile duct, raising suspicion for concurrent choledocholithiasis or cholangitis (McDermott et al., JAMA Surgery, 2024).

Signs of severe disease — persistent organ dysfunction, low blood pressure, confusion, or breathing difficulty — generally emerge within the first 24–48 hours and mark a higher-risk course (McDermott et al., JAMA Surgery, 2024).

‍

Diagnosis follows the Revised Atlanta Classification, requiring at least two of three criteria, then identifies gallstones as the cause (Fugazzola et al., EClinicalMedicine, 2024):

• Characteristic pain — acute, persistent, severe epigastric pain radiating to the back (Fugazzola et al., EClinicalMedicine, 2024).

• Serum lipase or amylase at least 3 times the upper limit of normal (Fugazzola et al., EClinicalMedicine, 2024).

• Characteristic imaging — findings of acute pancreatitis on CT, MRI, or ultrasound (Fugazzola et al., EClinicalMedicine, 2024).

To establish a biliary cause, testing focuses on (Tse & Yuan, Cochrane Database, 2012):

• Liver function tests — a ≥3-fold elevation in ALT has a ~95% positive predictive value for a biliary cause; however, 15–20% of patients with gallstone pancreatitis have normal liver tests, so a biliary origin cannot be excluded by normal labs alone (Tse & Yuan, Cochrane Database, 2012; Gardner, Yamada's Textbook of Gastroenterology, 2022).

• Transabdominal ultrasound — the first-line test for gallbladder stones; sensitivity is lower than usual (67–87%) in the setting of pancreatitis because of overlying bowel gas, but combined elevated liver tests plus gallstones on ultrasound yields a sensitivity of 95–98% (Tse & Yuan, Cochrane Database, 2012).

• MRCP or endoscopic ultrasound (EUS) — accurate, less-invasive tests for detecting a retained common bile duct stone when suspicion is intermediate (Şurlin et al., World Journal of Gastroenterology, 2014).

• Contrast-enhanced CT or MRI — reserved for assessing severity and complications such as necrosis, rather than for initial diagnosis (Fugazzola et al., EClinicalMedicine, 2024).

‍

Severe epigastric pain with elevated pancreatic enzymes must be distinguished from (Mederos et al., JAMA, 2021; McDermott et al., JAMA Surgery, 2024):

• Other causes of acute pancreatitis — alcohol, hypertriglyceridemia (typically >1,000 mg/dL), hypercalcemia, medications, post-ERCP, and hereditary pancreatitis

• Biliary colic and acute cholecystitis

• Choledocholithiasis and ascending cholangitis

• Peptic ulcer disease or perforated ulcer

• Acute hepatitis

• Bowel obstruction or mesenteric ischemia

• Inferior myocardial infarction — with epigastric presentation

• Periampullary or pancreatic tumors causing ductal obstruction

‍

Gallstone pancreatitis is an acute illness treated in the hospital, not with lifestyle change; however, the same measures that reduce gallstone formation lower the risk of developing it (and, importantly, during recovery the key "lifestyle" step is completing definitive treatment) (McDermott et al., JAMA Surgery, 2024):

• Maintain a healthy weight and avoid rapid/crash weight loss — and when major weight loss is planned (including after bariatric surgery), ursodeoxycholic acid can reduce gallstone formation (Gardner, Yamada's Textbook of Gastroenterology, 2022).

• Favor a higher-fiber, lower-refined-fat diet and manage metabolic risk factors (Gardner, Yamada's Textbook of Gastroenterology, 2022).

Once an attack has occurred, diet and lifestyle cannot substitute for gallbladder removal — without cholecystectomy, recurrence is common and can be more severe than the first episode (Mederos et al., JAMA, 2021).

‍

Management combines early supportive care with definitive source control through gallbladder removal (McDermott et al., JAMA Surgery, 2024):

• Initial supportive care — hospital admission, moderate (not aggressive) intravenous fluid resuscitation, pain control, and early oral feeding in mild cases; aggressive over-hydration is unnecessary and may be harmful (McDermott et al., JAMA Surgery, 2024).

• Early enteral nutrition — in severe disease, nutrition is delivered through a feeding tube (nasojejunal or nasogastric) within 48 hours; antibiotics are not given routinely and are reserved for suspected infection (Podda et al., MANCTRA Care Bundle, 2024).

• Same-admission (early) laparoscopic cholecystectomy — the definitive treatment for mild gallstone pancreatitis; multiple randomized trials support cholecystectomy during the index admission (often within 48 hours of admission), which reduces recurrent biliary events (gallstone-related complications 5% vs 17% with interval surgery), shortens hospital stay, and lowers cost without increasing operative complications (Tenner et al., ACG Guidelines, 2024; Trikudanathan et al., Gastroenterology, 2024).

• Delayed cholecystectomy in severe/necrotizing disease — when necrosis or peripancreatic fluid collections are present, surgery is deferred (often ~6 weeks) until inflammation subsides and collections resolve or stabilize, to avoid superinfection and technical difficulty (Mederos et al., JAMA, 2021; Portincasa & Wang, Yamada's Textbook of Gastroenterology, 2022).

• ERCP with sphincterotomy — selective, not routine — reserved for patients with concurrent cholangitis or persistent biliary obstruction (e.g., total bilirubin >4 mg/dL); in these cases, early ERCP (within ~24–72 hours) improves outcomes. Because most stones pass spontaneously, routine ERCP is not indicated in the absence of these features (McDermott et al., JAMA Surgery, 2024; Tenner et al., ACG Guidelines, 2024).

• Biliary sphincterotomy as an alternative — for patients who cannot undergo surgery (e.g., frail older adults with serious comorbidities), endoscopic sphincterotomy reduces the risk of recurrent biliary pancreatitis (Tenner et al., ACG Guidelines, 2024).

• Intraoperative cholangiography — performed during cholecystectomy to detect and clear any remaining bile duct stones (Tenner et al., ACG Guidelines, 2024).

‍

Anyone with sudden, severe upper-abdominal pain, particularly pain that bores through to the back and is accompanied by nausea and vomiting, should seek medical attention urgently, since this is the classic presentation of acute pancreatitis (Fugazzola et al., EClinicalMedicine, 2024). A known history of gallstones or prior biliary colic increases the likelihood of a biliary cause and warrants prompt evaluation (Gardner, Yamada's Textbook of Gastroenterology, 2022). Anyone who has recovered from an episode of gallstone pancreatitis should see a surgeon promptly about gallbladder removal, because the risk of recurrence is substantial without it (Mederos et al., JAMA, 2021).

‍

Seek emergency care for (Fugazzola et al., EClinicalMedicine, 2024; McDermott et al., JAMA Surgery, 2024):

• Severe, persistent epigastric pain radiating to the back

• Repeated vomiting and inability to keep down fluids

• Fever with jaundice — suggesting concurrent cholangitis, a biliary emergency

• Jaundice (yellow eyes/skin), dark urine, or clay-colored stools

• Confusion, difficulty breathing, low blood pressure, or a rapid heart rate — possible signs of severe pancreatitis with organ dysfunction or sepsis

These features indicate a potentially life-threatening emergency requiring hospital admission, laboratory and imaging evaluation, and — when infection or obstruction is present — urgent ERCP (Portincasa & Wang, Yamada's Textbook of Gastroenterology, 2022; Podda et al., MANCTRA Care Bundle, 2024).

‍

After recovery and gallbladder removal, the long-term outlook for mild gallstone pancreatitis is excellent, and most patients return to a normal, unrestricted diet (Portincasa & Wang, Yamada's Textbook of Gastroenterology, 2022). Removing the gallbladder is definitive: it addresses the source of the stones and dramatically reduces the risk of recurrent pancreatitis, cholecystitis, and cholangitis — complications that may otherwise occur in up to 30% of patients (Portincasa & Wang, Yamada's Textbook of Gastroenterology, 2022). Patients who have had severe or necrotizing disease may have a longer recovery and a risk of lasting pancreatic insufficiency (impaired digestion or diabetes), underscoring the value of care at an experienced center (McDermott et al., JAMA Surgery, 2024).

‍

The prognosis of gallstone pancreatitis depends chiefly on the severity of the initial episode (Fugazzola et al., EClinicalMedicine, 2024). Most patients (about 80%) have mild disease and recover fully, with a mortality of only around 1–2% (McDermott et al., JAMA Surgery, 2024; Fugazzola et al., EClinicalMedicine, 2024). Severe cases — those with necrosis, infected necrotizing pancreatitis, or multiorgan failure — carry a markedly higher mortality of 10–30%, influenced by severity, age, comorbidities, and the timeliness of treatment (Fugazzola et al., EClinicalMedicine, 2024). Early, appropriate care and prompt definitive treatment meaningfully improve outcomes (Fugazzola et al., EClinicalMedicine, 2024).

‍

Gallstone pancreatitis requires precise judgment about severity grading, the timing of surgery, and the selective use of ERCP — decisions that directly affect recurrence and outcomes (McDermott et al., JAMA Surgery, 2024). As a board-certified surgeon with advanced expertise in minimally invasive and robotic foregut and biliary surgery, Dr. Nestor de la Cruz-Muñoz, MD, FACS, DABOM assesses severity early, provides guideline-based supportive care, and, for mild disease, performs same-admission laparoscopic (or robotic) cholecystectomy — the strategy shown to reduce recurrent biliary events and shorten hospitalization (Tenner et al., ACG Guidelines, 2024; Trikudanathan et al., Gastroenterology, 2024). He reserves ERCP for patients with cholangitis or persistent biliary obstruction, uses intraoperative cholangiography to clear retained duct stones, and adheres to safe-cholecystectomy principles to minimize the risk of bile-duct injury (McDermott et al., JAMA Surgery, 2024; Portincasa & Wang, Yamada's Textbook of Gastroenterology, 2022). For patients with severe or necrotizing disease, he coordinates multidisciplinary care and appropriately timed, delayed cholecystectomy once inflammation has resolved (Mederos et al., JAMA, 2021).

‍